Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Enterprise Technology
  • Contract Manufacturing
  • R&D 100 Awards

U.S. pharma industry sees prescription sales dip again

By Brian Buntz | December 23, 2020

drug sales

Image courtesy of Christina Victoria Craft on Unsplash

The U.S. pharmaceutical market dipped 4.1% year-over-year in the most recent quarter-to-date figures, according to recent IQVIA research. New prescription sales fell 4.4%.

Brand-name drug sales, however, saw a modest growth rate of 1.8% while generic drug sales, which made up 80% of all sales, fell 4.5% in the quarter.

One bright spot in the most-recent quarter’s numbers is Johnson & Johnson’s (NYSE: JNJ) immunology segment. New prescription sales from the division were up 21.1%. Strong performers included dimethyl fumarate (Tecfidera), a multiple sclerosis therapy whose sales were up 23.4%. New prescription sales were even higher — up 47.7% — for the company’s fremanezumab-vfrm (Ajovy) migraine drug.

The overall dip in drug sales comes as the COVID-19 crisis gains momentum in the U.S. and elsewhere, sickening at least 18 million people. According to an assessment from the Economist, the novel coronavirus may have already infected nearly one in five Americans.

The COVID-19 pandemic could, however, provide a once-in-a-lifetime opportunity for the pharma industry to rebrand itself. The industry is already getting credit for “saving the world,” as Bloomberg recently concluded. COVID-19 vaccines alone could “prevent hundreds of thousands of American deaths and millions more around the world,” that publication concluded.

Tell Us What You Think! Cancel reply

Related Articles Read More >

Biden
Biden vows to ramp up COVID-19 vaccine distribution with $1.9T stimulus package
Amylyx
Amylyx hires new CFO 
pharmaceuticals
Unclear path for drug-pricing reform after Dem sweep 
Catalent
Catalent to acquire Acorda’s manufacturing and packaging operations 

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup

R&D Twitter

Tweets by @RandDWorld
Pharmaceutical Processing World
  • Enews Signup
  • Contact Us
  • About Us
  • R&D World
  • DeviceTalks
  • Drug Discovery & Development
  • Drug Delivery Business News
  • MassDevice
  • Medical Design Sourcing

Copyright © 2021 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Enterprise Technology
  • Contract Manufacturing
  • R&D 100 Awards